Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DV 100 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors DiaVacs

Most Recent Events

  • 16 Feb 2024 Planned End Date changed from 1 Jan 2019 to 16 Feb 2024.
  • 16 Feb 2024 Planned primary completion date changed from 1 Jul 2018 to 16 Feb 2024.
  • 16 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. ( Funding for study not procured.)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top